Empirical Finance LLC acquired a new stake in Amgen, Inc. (NASDAQ:AMGN) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 6,605 shares of the medical research company’s stock, valued at approximately $1,149,000.
A number of other large investors have also recently bought and sold shares of the stock. Baker Ellis Asset Management LLC purchased a new stake in shares of Amgen during the 3rd quarter worth $108,000. Jackson Grant Investment Advisers Inc. boosted its position in shares of Amgen by 0.8% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after purchasing an additional 5 shares in the last quarter. Phocas Financial Corp. purchased a new stake in shares of Amgen during the 2nd quarter worth $110,000. Omnia Family Wealth LLC boosted its position in shares of Amgen by 25.3% during the 2nd quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after purchasing an additional 147 shares in the last quarter. Finally, Salem Investment Counselors Inc. boosted its position in shares of Amgen by 4.7% during the 2nd quarter. Salem Investment Counselors Inc. now owns 809 shares of the medical research company’s stock worth $139,000 after purchasing an additional 36 shares in the last quarter. Hedge funds and other institutional investors own 79.61% of the company’s stock.
In related news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $174.18, for a total value of $265,624.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.19% of the company’s stock.
Amgen, Inc. (NASDAQ AMGN) opened at $189.75 on Wednesday. Amgen, Inc. has a one year low of $152.16 and a one year high of $201.23. The firm has a market cap of $136,402.42, a PE ratio of 15.05, a P/E/G ratio of 2.32 and a beta of 1.37. The company has a quick ratio of 5.17, a current ratio of 5.49 and a debt-to-equity ratio of 1.35.
Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing the consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.84 billion. During the same period in the previous year, the firm posted $2.89 EPS. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. equities analysts expect that Amgen, Inc. will post 13.24 earnings per share for the current fiscal year.
Amgen declared that its Board of Directors has authorized a stock repurchase plan on Thursday, February 1st that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the medical research company to buy shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s management believes its stock is undervalued.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be paid a $1.32 dividend. This represents a $5.28 annualized dividend and a yield of 2.78%. The ex-dividend date is Wednesday, May 16th. Amgen’s payout ratio is 205.45%.
ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2018/03/14/empirical-finance-llc-acquires-shares-of-6605-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.